Company profile for Exvastat

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Exvastat is an innovative, clinical-stage pharmaceutical company founded in 2016. The company is developing a treatment for acute respiratory distress syndrome (ARDS) based on a reformulation of imatinib (Impentri©) which is marketed worldwide as an oral treatment for chronic myeloid leukemia. The new treatment is based on the drug's ability to inhibit vascular leak, which drives the pulmonary oedema, and has been found to be...
Exvastat is an innovative, clinical-stage pharmaceutical company founded in 2016. The company is developing a treatment for acute respiratory distress syndrome (ARDS) based on a reformulation of imatinib (Impentri©) which is marketed worldwide as an oral treatment for chronic myeloid leukemia. The new treatment is based on the drug's ability to inhibit vascular leak, which drives the pulmonary oedema, and has been found to be effective in a number of human case reports as well as in vivo models (see here). Impentri has the potential to significantly reduce the high mortality and incapacitating morbidities caused by ARDS, as well as costs.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
United Kingdom
Address
Address
Idea Space South, Cambridge Biomedical Campus, Bay 13 Hills Rd. Cambridge, CB2...
Telephone
Telephone
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Cosmoprof

Cosmoprof

Not Confirmed

envelop Contact Supplier

Cosmoprof

Post an Enquiry

Meeting

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty